Notice of Interim Results

25 September 2013

Instem plc
("Instem", the "Company" or the "Group")

Notice of Interim Results

Instem plc (AIM: INS), a leading provider of IT solutions to the global early development healthcare market, will be announcing its unaudited interim results for the six months ended 30 June 2013, on Wednesday 25 September 2013.

Management will be hosting a presentation for analysts on the day of results at 11am at the offices of N+1 Singer: One Bartholomew Lane, London, EC2N 2AX.

Analysts who wish to attend the presentation should register their interest with Jasper Randall, contactable at j.randall@newgatethreadneedle.com or 020 7653 9845.

For further information, please contact:

Instem plc	www.instem.com
Phil Reason, CEO	+44 (0) 1785 825600
Nigel Goldsmith, CFO
N+1 Singer (Nominated Adviser & Broker)	+44 (0) 20 7496 3000
Richard Lindley
Nick Owen
James White
Wallbrook Financial PR	Tel: +44 (0) 20 7933 8000
Paul Cornelius	or instem@walbrookpr.com
Sam Allen
Helen Cresswell
Paul Whittington

About Instem

Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidlyexpanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.

Instem’s portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.

Instem supports over 450 clients through full service offices in the United States, United Kingdom and China with additional locations in Japan and India.

To learn more about Instem solutions and its mission, please visit instem.com.